secwatch.observer — SEC 8-K summary
======================================

Issuer:     RIGEL PHARMACEUTICALS INC (RIGL)
CIK:        0001034842
Form:       8-K
Filed at:   2024-11-07T23:59:59+00:00
Accession:  0001104659-24-115334
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Rigel Q3 net income $12.4M vs year-ago loss; revenue $55.3M, led by TAVALISSE +8%
--------------------------------------------------------------------------------

- Total Q3 revenue $55.3M; net income $12.4M ($0.71 basic EPS) vs net loss $5.7M in Q3 2023.
- TAVALISSE net sales $26.3M (+8% YoY); REZLIDHIA $5.5M (+107% YoY); GAVRETO $7.1M (first full quarter).
- Received $10M upfront from Kissei license for REZLIDHIA in Japan, Korea, Taiwan; up to $152.5M milestones.
- R289 Phase 1b in LR-MDS: RBC-TI/hematologic improvement in 36% at doses ≥500 mg QD; median duration 29 weeks.
- Cash and investments $61.1M at Sep 30, up from $49.1M at Jun 30 and $56.9M at Dec 31, 2023.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1034842/000110465924115334/0001104659-24-115334-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1034842/000110465924115334/tm2427717d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-24-115334

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer